Skip to content
2000
image of Unveiling Vadadustat: Comprehensive Review of its Chemistry, Pharmacology, Bioanalysis, and Patent Landscape as a Novel HIF-PH Inhibitor

Abstract

Introduction

The goal of this study is to provide a comprehensive review of physicochemical and pharmacological properties, including pharmacokinetics and pharmacodynamics parameters, with an overview of preclinical and clinical trial data, chemistry, and multiple routes of synthesis, bioanalytical methods, and patents of the API: Vadadustat

Methods

A review was conducted by compiling data from Science Direct, PubMed, Drug Bank, WIPO patent, Clinicaltrialgov, Wolters Kluwer, and many others to enhance understanding of the topic

Results

The FDA approved Vadadustat on March 27, 2024, for treating anemia in adults with CKD on dialysis. Vadadustat effectively increased hemoglobin levels in both non-dialysis and dialysis-dependent CKD patients. It showed comparable efficacy to traditional erythropoiesis-stimulating agents (ESAs) like darbepoetin alfa. Multiple clinical trials, including Phase 2 and Phase 3 studies, demonstrated Vadadustat’s potential as an effective treatment for anemia in CKD patients.

Discussion

Vadadustat, as an oral HIF-PH inhibitor, offers significant advantages in the treatment of anemia in CKD. Its oral route of administration improves patient compliance, and its efficacy is comparable to ESAs. Clinical and preclinical data support its safety and therapeutic potential, although long-term cardiovascular effects remain under observation.

Conclusion

This review examines therapeutic, pharmacological, analytical, and regulatory aspects related to Vadadustat.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266366384250716121432
2025-07-22
2025-09-23

  • From This Site

    /content/journals/ctmc/10.2174/0115680266366384250716121432
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Vaidya S.R. Aeddula N.R. Chronic Kidney Disease. 2nd ed The Scientific Basis of Urology 2024 257 264
    [Google Scholar]
  2. Portolés J. Martín L. Broseta J.J. Cases A. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents. Front. Med. 2021 8 642296 10.3389/fmed.2021.642296 33842503
    [Google Scholar]
  3. Akebia receives FDA approval of vafseo® (vadadustat) tablets for the treatment of anemia due to chronic kidney disease in adult patients on dialysis | akebia therapeutics. 2024 Available from: https://ir.akebia.com/news-releases/news-release-details/akebia-receives-fda-approval-vafseor-vadadustat-tablets
  4. Vadadustat. 2025 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Vadadustat
  5. Davis A.M. Leeson P.D. Physicochemical properties. The Handbook of Medicinal Chemistry. The Royal Society of Chemistry 2023 1 39
    [Google Scholar]
  6. Burger H-J. Schwenk M. Importance of physicochemical and physical properties for toxicological risk assessment. Regulatory Toxicology. Cham Springer International Publishing 2021 697 715 10.1007/978‑3‑030‑57499‑4_113
    [Google Scholar]
  7. Available from: https://go.drugbank.com/drugs/DB12255
  8. Navarro-Gonzales P. Ganz T. Pergola P.E. Zuk A. Dykstra K. Pharmacokinetics, pharmacodynamics, and safety of vadadustat in healthy volunteers and patients with chronic kidney disease. Clin. Pharmacol. Ther. 2024 116 4 1052 1061 10.1002/cpt.3342 38924087
    [Google Scholar]
  9. Markham A. Vadadustat: First approval. Drugs 2020 80 13 1365 1371 10.1007/s40265‑020‑01383‑z 32852744
    [Google Scholar]
  10. Kowalski H. Hoivik D. Rabinowitz M. Assessing the carcinogenicity of vadadustat, an oral hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, in rodents. Toxicol. Pathol. 2023 51 1-2 56 60 10.1177/01926233231168836 37158494
    [Google Scholar]
  11. Zuk A. Si Z. Loi S. Bommegowda S. Hoivik D. Danthi S. Molnar G. Csizmadia V. Rabinowitz M. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J. Pharmacol. Exp. Ther. 2022 383 1 11 24 10.1124/jpet.122.001126 35926869
    [Google Scholar]
  12. Hanudel M.R. Wong S. Jung G. Qiao B. Gabayan V. Zuk A. Ganz T. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. Kidney Int. 2021 100 1 79 89 10.1016/j.kint.2021.03.019 33811979
    [Google Scholar]
  13. Parfrey P.S. Burke S.K. Chertow G.M. Eckardt K.U. Jardine A.G. Lewis E.F. Luo W. Matsushita K. McCullough P.A. Minga T. Winkelmayer W.C. Safety endpoints with vadadustat versus darbepoetin alfa in patients with non–dialysis-dependent CKD: A post hoc regional analysis of the PRO2TECT randomized clinical trial of ESA-treated patients. Kidney Med. 2023 5 7 100667 10.1016/j.xkme.2023.100667 37427292
    [Google Scholar]
  14. Kokado Y. Kawai K. Nanjo T. Kinoshita S. Kondo K. In vitro and clinical pharmacokinetic studies of the effects of iron-containing agents on vadadustat, an oral hypoxia-inducible factor–prolyl hydroxylase inhibitor. Clin. Ther. 2021 43 8 1408 1418.e5 10.1016/j.clinthera.2021.06.013 34511184
    [Google Scholar]
  15. Nangaku M. Farag Y.M.K. deGoma E. Luo W. Vargo D. Khawaja Z. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrol. Dial. Transplant. 2021 36 7 1244 1252 10.1093/ndt/gfaa060 32719868
    [Google Scholar]
  16. Chertow G.M. Pergola P.E. Farag Y.M.K. Agarwal R. Arnold S. Bako G. Block G.A. Burke S. Castillo F.P. Jardine A.G. Khawaja Z. Koury M.J. Lewis E.F. Lin T. Luo W. Maroni B.J. Matsushita K. McCullough P.A. Parfrey P.S. Roy-Chaudhury P. Sarnak M.J. Sharma A. Spinowitz B. Tseng C. Tumlin J. Vargo D.L. Walters K.A. Winkelmayer W.C. Wittes J. Eckardt K.U. PRO2TECT Study Group Vadadustat in patients with anemia and non–dialysis-dependent CKD. N. Engl. J. Med. 2021 384 17 1589 1600 10.1056/NEJMoa2035938 33913637
    [Google Scholar]
  17. Nangaku M. Kondo K. Kokado Y. Ueta K. Kaneko G. Tandai T. Kawaguchi Y. Komatsu Y. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in japanese patients with nondialysis-dependent CKD. J. Am. Soc. Nephrol. 2021 32 7 1779 1790 10.1681/ASN.2020091311 33883252
    [Google Scholar]
  18. Nangaku M. Kondo K. Ueta K. Kokado Y. Kaneko G. Matsuda H. Kawaguchi Y. Komatsu Y. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: A Phase 3, multicenter, randomized, double-blind study. Nephrol. Dial. Transplant. 2021 36 9 1731 1741 10.1093/ndt/gfab055 33650630
    [Google Scholar]
  19. Martin E.R. Smith M.T. Maroni B.J. Zuraw Q.C. deGoma E.M. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am. J. Nephrol. 2017 45 5 380 388 10.1159/000464476 28343225
    [Google Scholar]
  20. Pergola P.E. Spinowitz B.S. Hartman C.S. Maroni B.J. Haase V.H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 90 5 1115 1122 10.1016/j.kint.2016.07.019 27650732
    [Google Scholar]
  21. Study to evaluate the safety and efficacy of oral vadadustat in pediatric participants with anemia of chronic kidney disease. patent NCT05082571 2023
  22. Study to evaluate the safety and efficacy of oral vadadustat in pediatric participants with anemia of chronic kidney disease naive to erythropoiesis-stimulating agents (correction). patent NCT05082584 2023
  23. Study to evaluate vadadustat for anemia in subjects with dialysis-dependent chronic kidney disease (dd-ckd) who are hyporesponsive to erythropoiesis stimulating agents. patent NCT03140722 2021
  24. Eckardt K.U. Agarwal R. Aswad A. Awad A. Block G.A. Bacci M.R. Farag Y.M.K. Fishbane S. Hubert H. Jardine A. Khawaja Z. Koury M.J. Maroni B.J. Matsushita K. McCullough P.A. Lewis E.F. Luo W. Parfrey P.S. Pergola P. Sarnak M.J. Spinowitz B. Tumlin J. Vargo D.L. Walters K.A. Winkelmayer W.C. Wittes J. Zwiech R. Chertow G.M. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N. Engl. J. Med. 2021 384 17 1601 1612 10.1056/NEJMoa2025956 33913638
    [Google Scholar]
  25. Lin B. Kou J. Wu S. Cai X. Xiao Q. Li Y. Hu J. Li J. Wang Z. Development of a robust and scalable process for the large-scale preparation of vadadustat. Org. Process Res. Dev. 2021 25 4 960 968 10.1021/acs.oprd.1c00004
    [Google Scholar]
  26. Yokoyama S. Nakagawa J. Shimada M. Ueno K. Ishiyama M. Nakamura N. Tomita H. Niioka T. Quantification of the plasma concentration of vadadustat by high-performance liquid chromatography with ultraviolet detection and ultra-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 2024 46 6 813 819 10.1097/FTD.0000000000001238 38953704
    [Google Scholar]
  27. Focusing energy. Available from: https://www.uspto.gov/
  28. Polymorphic forms of vadadustat. patent WO2020075199 2020
  29. A process for the preparation of vadadustat or salts thereof. WO patent 2024079708 2024
  30. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat. WO patent 2022006427 2024
  31. Method for producing vadadustat intermediate. WO patent 2020217733 2024
  32. Therapeutic methods using vadadustat. WO patent 2021087144A1 2024
  33. Novel crystalline compound of vadadustat. WO patent 2021250624A1 2024
  34. Vadadustat for treating COVID-19 in a hospitalized subject. WO patent 2022179967 2024
  35. Modulation of drug-drug interactions of vadadustat. WO patent 2021257800 2024
  36. Crystalline forms of vadadustat and methods for their preparation. WO patent 2022018450 2024
  37. Method for preparing vadadustat and intermediate thereof. WO patent 2021179540 2024
  38. Amorphous solid dispersions of vadadustat and co-crystal of vadadustat with nicotinamide. IN patent 202041018360 2024
  39. Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid. EP patent 3790863A1 2024
/content/journals/ctmc/10.2174/0115680266366384250716121432
Loading
Unveiling Vadadustat: Comprehensive Review of its Chemistry, Pharmacology, Bioanalysis, and Patent Landscape as a Novel HIF-PH Inhibitor
Bentham Science Publishers ; https://doi.org/10.2174/0115680266366384250716121432
/content/journals/ctmc/10.2174/0115680266366384250716121432
/content/journals/ctmc/10.2174/0115680266366384250716121432
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Vadadustat ; CKD ; HIF-PH Inhibitor ; Chemistry ; Bioanalysis ; Patents

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test